Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030

Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030


The Angina Pectoris Drugs Market size was estimated at USD 1.14 billion in 2023 and expected to reach USD 1.20 billion in 2024, at a CAGR 5.39% to reach USD 1.65 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Angina Pectoris Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angina Pectoris Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

Prinzmetal Angina
  • Stable Angina
  • Unstable Angina
  • Drugs

    Anti-Ischemic Agents
  • Antihypertensive Agents
  • Antiplatelet Agents
  • Beta-Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Nitrates
  • Statins
  • Route of Administration

    Oral
  • Parenteral
  • Transdermal
  • Distribution Channel

    Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • End-Users

    Homecare
  • Hospitals
  • Specialty Clinics
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Angina Pectoris Drugs Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angina Pectoris Drugs Market?
    3. What are the technology trends and regulatory frameworks in the Angina Pectoris Drugs Market?
    4. What is the market share of the leading vendors in the Angina Pectoris Drugs Market?
    5. Which modes and strategic moves are suitable for entering the Angina Pectoris Drugs Market?


    Note: PDF & Excel + Online Access - 1 Year

  • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Angina Pectoris Drugs Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
    5.1.1.2. Augmentation of novel drug delivery systems
    5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
    5.1.2. Restraints
    5.1.2.1. Concerns regarding side effects associated with certain drug classes
    5.1.3. Opportunities
    5.1.3.1. Technological advancements towards personalized cardiovascular medicine
    5.1.3.2. Proliferation in the number of drug approvals and clinical research
    5.1.4. Challenges
    5.1.4.1. Dearth of skilled and experienced professionals
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Angina Pectoris Drugs Market, by Type
    6.1. Introduction
    6.2. Prinzmetal Angina
    6.3. Stable Angina
    6.4. Unstable Angina
    7. Angina Pectoris Drugs Market, by Drugs
    7.1. Introduction
    7.2. Anti-Ischemic Agents
    7.3. Antihypertensive Agents
    7.4. Antiplatelet Agents
    7.5. Beta-Adrenergic Blocking Agents
    7.6. Calcium Channel Blockers
    7.7. Nitrates
    7.8. Statins
    8. Angina Pectoris Drugs Market, by Route of Administration
    8.1. Introduction
    8.2. Oral
    8.3. Parenteral
    8.4. Transdermal
    9. Angina Pectoris Drugs Market, by Distribution Channel
    9.1. Introduction
    9.2. Hospital Pharmacy
    9.3. Online Pharmacy
    9.4. Retail Pharmacy
    10. Angina Pectoris Drugs Market, by End-Users
    10.1. Introduction
    10.2. Homecare
    10.3. Hospitals
    10.4. Specialty Clinics
    11. Americas Angina Pectoris Drugs Market
    11.1. Introduction
    11.2. Argentina
    11.3. Brazil
    11.4. Canada
    11.5. Mexico
    11.6. United States
    12. Asia-Pacific Angina Pectoris Drugs Market
    12.1. Introduction
    12.2. Australia
    12.3. China
    12.4. India
    12.5. Indonesia
    12.6. Japan
    12.7. Malaysia
    12.8. Philippines
    12.9. Singapore
    12.10. South Korea
    12.11. Taiwan
    12.12. Thailand
    12.13. Vietnam
    13. Europe, Middle East & Africa Angina Pectoris Drugs Market
    13.1. Introduction
    13.2. Denmark
    13.3. Egypt
    13.4. Finland
    13.5. France
    13.6. Germany
    13.7. Israel
    13.8. Italy
    13.9. Netherlands
    13.10. Nigeria
    13.11. Norway
    13.12. Poland
    13.13. Qatar
    13.14. Russia
    13.15. Saudi Arabia
    13.16. South Africa
    13.17. Spain
    13.18. Sweden
    13.19. Switzerland
    13.20. Turkey
    13.21. United Arab Emirates
    13.22. United Kingdom
    14. Competitive Landscape
    14.1. FPNV Positioning Matrix
    14.2. Market Share Analysis, By Key Player
    14.3. Competitive Scenario Analysis, By Key Player
    15. Competitive Portfolio
    15.1. Key Company Profiles
    15.1.1. Alembic Pharmaceuticals Limited
    15.1.2. Alkem Laboratories Ltd.
    15.1.3. Astellas Pharma Inc.
    15.1.4. AstraZeneca PLC
    15.1.5. Bausch Health Companies Inc.
    15.1.6. Bayer AG
    15.1.7. Centurion Remedies Private Limited
    15.1.8. Dr. Reddy's Laboratories
    15.1.9. Eli Lilly and Company
    15.1.10. Gilead Sciences, Inc.
    15.1.11. GlaxoSmithKline PLC
    15.1.12. Intas Pharmaceuticals Ltd.
    15.1.13. Ipca Laboratories Ltd.
    15.1.14. Lupin Ltd.
    15.1.15. Macleods Pharmaceuticals Pvt Ltd.
    15.1.16. Mankind Pharma
    15.1.17. Merck & Co. Inc.
    15.1.18. Novartis AG
    15.1.19. Otsuka Pharmaceutical Co., Ltd.
    15.1.20. Pfizer Inc.
    15.1.21. Sanofi-Aventis Groupe S.A.
    15.1.22. Sumitomo Corporation
    15.1.23. Sun Pharmaceutical Industries Ltd.
    15.1.24. Teva Pharmaceutical Industries Ltd.
    15.1.25. Torrent Pharmaceuticals Ltd.
    15.2. Key Product Portfolio
    16. Appendix
    16.1. Discussion Guide
    16.2. License & Pricing
    FIGURE 1. ANGINA PECTORIS DRUGS MARKET RESEARCH PROCESS
    FIGURE 2. ANGINA PECTORIS DRUGS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANGINA PECTORIS DRUGS MARKET DYNAMICS
    FIGURE 7. ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
    FIGURE 8. ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
    FIGURE 10. ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 12. ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
    FIGURE 14. ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
    FIGURE 16. ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 20. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 25. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 26. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings